4D pharma merging with Longevity

22 October 2020

UK-based 4D pharma (AIM: DDDD), which is leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome - and Longevity Acquisition Corp (Nasdaq: LOAC) today announce the proposed merger of the two companies.

The news saw 4D pharma shares leap 21.6% to 113.35 pence as markets closed, while Longevity dipped 0.75% to $10.60 in late-morning New York trading.

The deal is worth up to $37.6 million to 4D pharma. As a result of the merger, 4D pharma plans to launch a new Nasdaq-listed American Depositary Share (ADS) program under the ticker symbol ‘LBPS’ and will immediately be admitted to trading on Nasdaq upon completion. 4D pharma will become dual-listed and ordinary shares will continue to be traded on AIM under the ticker symbol ‘DDDD’.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK